HERC5 Antibodies

E3 ISG15--protein ligase HERC5 (HERC5)

Acts as a positive regulator of innate antiviral response in cells induced by interferon. Functions as part of the ISGylation machines that recognizes target proteins in a broad and comparatively non-specific manner.

Catalyzes ISGylation of IRF3 which leads to sustained activation, it attenuates IRF3-PIN1 interaction, which antagonizes IRF3 ubiquitination and degradation, and boosts the antiviral response. Catalyzes ISGylation of influenza A viral NS1 that attenuates virulence; ISGylated NS1 fails to form homodimers and thus to interact with its RNA targets.

Gene Information

Human
Gene Name:	HERC5
Uniprot:	Q9UII4
Entrez:	51191

Family

Belongs to:
No superfamily

Alternative Names

CEB1E3 ISG15--protein ligase HERC5; CEBP1; cyclin-E binding protein 1; Cyclin-E-binding protein 1; EC 6.3.2; EC 6.3.2.-; HECT domain and RCC1-like domain-containing protein 5; hect domain and RLD 5; HECT E3 ubiquitin ligase; probable E3 ubiquitin-protein ligase HERC5

Molecular Weight

Mass (kDA):
116.852 kDA

Genomic Context

Human
Location:	4q22.1
Sequence:	4; NC_000004.12 (88456604..88506170)

Tissue Specificity

Expressed in testis and to a lesser degree in brain, ovary and placenta. Found in most tissues at low levels.

Subcellular Localizations

Cytoplasm, perinuclear region. Associated with the polyribosomes, probably via the 60S subunit.

Diseases

• Influenza
• Innate Immune Response
• Hiv Infections
• Malignant Neoplasms
• Neoplasms
• Bacterial Infections
• Germline Mutation Abnormality
• Autoimmune Diseases
• Carcinogenesis
• Infective Disorder
• Virus Diseases
• Autoimmune Reaction

• Leukemia
• Sclerosis
• Neoplasm Metastasis
• Malignant Neoplasm Of Breast
• Hepatitis C, Chronic
• Dermatomyositis
• Premature Aging Syndrome

Pathways

• Conjugation
• Cell Cycle
• Pathogenesis
• Osteoclast Differentiation
• Cell Proliferation
• Cellular Senescence
• Immune Response
• Dna Repair
• Neuron Differentiation
• Virulence
• Localization
• Cell Cycle Arrest

• Senescence
• S Phase
• Mitotic Recombination
• Chromosome Condensation
• Viral Replication
• Nuclear Import

PTMs

• Isgylation

• Ubiquitination

Research Areas

• Cell Cycle and Replication

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/HERC5

Boster Bio - Best Uses Of The HERC5 Marker

If you're an immunologist looking to produce antibodies against HBV and/or HCV, you've probably come across the HERC5 Marker. But did you know there are other applications for this protein? If not, you'll want to learn more about Boster Bio's high-affinity primary antibodies. Read on to learn more. Here are some best uses for the HERC5 Marker.

HERC5 Marker

The Herc5 (HERC-5) protein is essential for conjugation of ISG15 to a broad range of target proteins in human cells. Its central role in this system is supported by the fact that Herc5 is induced by IFN-b. Furthermore, Herc5 acts as an ISG15 ligase and catalyzes the conjugation of ISG15 to target proteins. Recent proteomic analyses of ISG15-conjugated proteins suggest that Herc5 is required for this conjugation system.

Several transcriptomic studies have identified gene signatures that predict HCC outcome. However, the HERC5 gene is not the only gene associated with outcome. The gene is positioned within large somatic copy number deletions in both PTs and RTs. Moreover, the HERC5 gene expression was significantly decreased in HCC patients with tumor recurrence. However, this association is limited to a small number of cases, since DNA sequencing was not performed on 17 patients.

HERC5 was detected in both HeLa and 293 cells in Dulbecco's modified Eagle's medium. The constructs to express Ube1L, ISG15, and UbcH8 were described previously. We used a plasmid containing Herc5 open reading frame, provided by M. Ohtsubo. The plasmid containing the Herc5 open reading frame was subcloned into pcDNA3 vector containing a TAP tag. Anti-p56 and anti-MxA antibodies were provided by Ganes Sen and Otto Haller.

The HERC5 gene has important implications in the immune evasion of HCC. Its characterization as a prognostic marker has clinical significance. It can predict tumor recurrence or survival. By testing for HERC5, it may be possible to identify patients at a lower risk for recurrence or death. However, more research is needed to validate the utility of the HERC5 gene in this context.

HERC5 Marker for HBV production

Recently, researchers have discovered that the HERC5 Marker is responsible for HBV production in some human patients. Although its precise role in the production of HBV is not fully understood, it is thought to be involved in immune escape and the development of resistance to antiviral drugs. This new discovery has a multitude of implications for the treatment of HBV. It also highlights the importance of conducting studies in larger samples of human patients.

Although HBV is prevalent in many parts of the world, prevalence rates are different between the East/Southeast Asian region and the Western world. Prior to the HBV vaccine program, the prevalence of HBsAg was as high as 10% in the Chinese population, while it was less than one percent in Caucasians. The reasons for this difference are unclear, although they may involve the role of host genetic determinants.

Using an in vitro infection system that is compatible with the HBV genome and the hepatic cells used in the experiments is vital to studying the pathogenesis of the disease. Recent advances in the study of HBV and hepatitis B provide hope for further study of the infection and its effects on the liver. While antiviral drugs can kill HBV, no effective treatment for chronic infection is available. Thus, the goal of this study is to develop an effective HBV infection model.

Despite the numerous studies conducted to date, it is unclear whether these biomarkers will have clinical significance. However, they are useful for diagnosing patients at high risk for HBV reactivation or inducing immune-suppressive drugs. Eventually, they may replace the current HBV-DNA testing method. And, in the meantime, they are useful for patient monitoring during immunosuppressive treatments.

The results of this study suggest that HERC5 Marker is a biomarker of infection with hepatitis B virus. Its mutational profile has been used to identify patients at high risk for HBV-R. Several studies have shown that HBsAg has high genetic variability among patients with immune-suppressive HBV-R. Further studies have shown that specific genetic signatures of the HBsAg are associated with HBV-R.

HERC5 Marker for HCV production

In the present study, we have used a seronegative infected human subject to test the potential of the HERC5 Marker for HCV Production. The results show that this antigen is highly immunogenic for HCV. Hence, we hypothesize that the presence of the HERC5 Marker for HCV production may help in the identification of aviremic infected subjects.

The HERC5 Marker for HCV Production is an essential component of the antiviral immune response in humans. It inhibits the replication of HCV by binding to the NS5A protein. This marker is a crucial component of the HERC protein family, which replicates in the vicinity of ER membranes and forms a lipid droplet-associated replication complex. Infection with HERC5 is the first sign of a new HCV outbreak.

When exposed to HCV, PBMCs from infected individuals with chronic and self-limited infection showed a Th2-type cytokine profile. Th2 responses were higher in acute infection, but these disappeared after a year of chronic HCV infection. In contrast, responses to Th2 cytokines were reduced after treatment with IFN-a. This result indicates that the antigen-specific T cell response of an infected individual during acute HCV infection is important for the control of the disease.

The current knowledge of spontaneous clearance of HCV infection is incomplete. Researchers continue to be optimistic despite the limited knowledge of the virus. The high viral replication rate and the seven genotypes have hampered the development of an effective vaccine. A lack of funds, modest interest by pharmaceutical companies and the difficulty of developing a small and convenient animal model have all contributed to the long wait for an effective HCV vaccine.

HERC5 Marker for HCV Production may help in the identification of new drug candidates. It is crucial to identify and evaluate the targets of HCV-NS5A infection and to identify the best treatments to combat this viral infection. Further research is needed to understand the regulatory role of HERC5 Marker for HCV production. So, what is HERC5 and how can it be used to fight the disease?

Boster offers high-affinity primary antibodies

The HERC5 marker is a cancer-specific receptor and is used in many different types of research. High-affinity antibodies are required to detect this marker in cancer cells and other samples. The Boster antibodies are polyclonal or monoclonal and are highly cited in the scientific literature. Using high-affinity antibodies to detect this cancer-specific receptor is a powerful method.

Primary antibodies are immunoglobulins derived from the immune systems of their host animals. They contain a region called complementarity-determining regions. Learn more about this region on Wikipedia. In the production of primary antibodies, scientists immunize host animals with antigens and then extract the antibodies from the eggs and sera of the host animals. This enables them to detect, measure, and purify the antigen of interest.